Cagrilintide

Long-acting amylin analog — extends GLP-1 effects via additional satiety and gastric-emptying signals.

Cagrilintide copies amylin, a second satiety hormone the pancreas releases alongside insulin — a different "you're full" pathway from GLP-1. On its own it's a decent appetite suppressant, but its real role is as a multiplier: stacked with a GLP-1 drug it deepens the weight loss and often softens the nausea, because two satiety signals let you get more effect at a lower GLP dose. That's the logic behind CagriSema (with Semaglutide) and the researched Retatrutide and Tirzepatide combos.

Dose

Weekly titration, often half the GLP partner's dose.

Reconstitute

Standard.

Schedule

Weekly, paired with GLP day.

Half-life

~7 days.

Timing

Same day as GLP partner.

Risks

Mild GI. Hypoglycemia risk when stacked.

Educational reference — not medical advice. Many peptides are not approved for the uses discussed; verify status in your jurisdiction and decide anything here with a qualified clinician.

within Weight Loss & GLP Class